<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250209031203&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250209031203&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 09 Feb 2025 08:12:06 +0000</lastbuilddate>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Novel pharmacological approaches to lowering blood pressure and managing hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39920248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>Hypertension is the leading cause of death globally, primarily due to its strong association with cardiovascular disease. The global prevalence of hypertension has surged over the past three decades, driven by rising rates of diabetes mellitus and obesity. Despite current antihypertensive therapies, only a small proportion of patients with hypertension achieve adequate blood pressure control, necessitating novel therapeutic strategies. In this Review we explore the challenges and emerging...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 7. doi: 10.1038/s41569-025-01131-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hypertension is the leading cause of death globally, primarily due to its strong association with cardiovascular disease. The global prevalence of hypertension has surged over the past three decades, driven by rising rates of diabetes mellitus and obesity. Despite current antihypertensive therapies, only a small proportion of patients with hypertension achieve adequate blood pressure control, necessitating novel therapeutic strategies. In this Review we explore the challenges and emerging opportunities in hypertension management. Aprocitentan, a dual endothelin receptor antagonist, is the first agent from a novel class of antihypertensive drug to be licensed since 2007 and exemplifies innovative treatments on the horizon. Here we also address the complex factors contributing to poor hypertension control, including genetic influences, lifestyle factors, therapeutic inertia and poor patient adherence. We discuss the limitations of existing therapies and highlight promising new pharmacological approaches to hypertension management. Integrating these novel treatments alongside current pharmaceuticals combined with improved diagnostic and management strategies could substantially reduce the global burden of hypertension and associated cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39920248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39920248</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01131-4>10.1038/s41569-025-01131-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39920248</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Matthew Sayer</dc:creator>
<dc:creator>David J Webb</dc:creator>
<dc:creator>Neeraj Dhaun</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Novel pharmacological approaches to lowering blood pressure and managing hypertension</dc:title>
<dc:identifier>pmid:39920248</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01131-4</dc:identifier>
</item>
<item>
<title>Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39920247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 7. doi: 10.1038/s41569-025-01134-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39920247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39920247</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01134-1>10.1038/s41569-025-01134-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39920247</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Elizabeth Figueroa-Juárez</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition</dc:title>
<dc:identifier>pmid:39920247</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01134-1</dc:identifier>
</item>
<item>
<title>Vagal circuits in the heart and gut can regulate cardiometabolism and stress responses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39920246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 7. doi: 10.1038/s41569-025-01133-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39920246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39920246</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01133-2>10.1038/s41569-025-01133-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39920246</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Vagal circuits in the heart and gut can regulate cardiometabolism and stress responses</dc:title>
<dc:identifier>pmid:39920246</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01133-2</dc:identifier>
</item>
<item>
<title>GUK1 activation is a metabolic liability in lung cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39919745/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>Little is known about metabolic vulnerabilities in oncogene-driven lung cancer. Here, we perform a phosphoproteomic screen in anaplastic lymphoma kinase (ALK)-rearranged ("ALK+") patient-derived cell lines and identify guanylate kinase 1 (GUK1), a guanosine diphosphate (GDP)-synthesizing enzyme, as a target of ALK signaling in lung cancer. We demonstrate that ALK binds to and phosphorylates GUK1 at tyrosine 74 (Y74), resulting in increased GDP biosynthesis. Spatial imaging of ALK+ patient tumor...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 28:S0092-8674(25)00093-5. doi: 10.1016/j.cell.2025.01.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Little is known about metabolic vulnerabilities in oncogene-driven lung cancer. Here, we perform a phosphoproteomic screen in anaplastic lymphoma kinase (ALK)-rearranged ("ALK+") patient-derived cell lines and identify guanylate kinase 1 (GUK1), a guanosine diphosphate (GDP)-synthesizing enzyme, as a target of ALK signaling in lung cancer. We demonstrate that ALK binds to and phosphorylates GUK1 at tyrosine 74 (Y74), resulting in increased GDP biosynthesis. Spatial imaging of ALK+ patient tumor specimens shows enhanced phosphorylation of GUK1 that significantly correlates with guanine nucleotides in situ. Abrogation of GUK1 phosphorylation reduces intracellular GDP and guanosine triphosphate (GTP) pools and decreases mitogen-activated protein kinase (MAPK) signaling and Ras-GTP loading. A GUK1 variant that cannot be phosphorylated (Y74F) decreases tumor proliferation in vitro and in vivo. Beyond ALK, other oncogenic fusion proteins in lung cancer also regulate GUK1 phosphorylation. These studies may pave the way for the development of new therapeutic approaches by exploiting metabolic dependencies in oncogene-driven lung cancers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39919745/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39919745</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.024>10.1016/j.cell.2025.01.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39919745</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jaime L Schneider</dc:creator>
<dc:creator>Kiran Kurmi</dc:creator>
<dc:creator>Yutong Dai</dc:creator>
<dc:creator>Ishita Dhiman</dc:creator>
<dc:creator>Shakchhi Joshi</dc:creator>
<dc:creator>Brandon M Gassaway</dc:creator>
<dc:creator>Christian W Johnson</dc:creator>
<dc:creator>Nicole Jones</dc:creator>
<dc:creator>Zongyu Li</dc:creator>
<dc:creator>Christian P Joschko</dc:creator>
<dc:creator>Toshio Fujino</dc:creator>
<dc:creator>Joao A Paulo</dc:creator>
<dc:creator>Satoshi Yoda</dc:creator>
<dc:creator>Gerard Baquer</dc:creator>
<dc:creator>Daniela Ruiz</dc:creator>
<dc:creator>Sylwia A Stopka</dc:creator>
<dc:creator>Liam Kelley</dc:creator>
<dc:creator>Andrew Do</dc:creator>
<dc:creator>Mari Mino-Kenudson</dc:creator>
<dc:creator>Lecia V Sequist</dc:creator>
<dc:creator>Jessica J Lin</dc:creator>
<dc:creator>Nathalie Y R Agar</dc:creator>
<dc:creator>Steven P Gygi</dc:creator>
<dc:creator>Kevin M Haigis</dc:creator>
<dc:creator>Aaron N Hata</dc:creator>
<dc:creator>Marcia C Haigis</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>GUK1 activation is a metabolic liability in lung cancer</dc:title>
<dc:identifier>pmid:39919745</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.024</dc:identifier>
</item>
<item>
<title>Tumor "age" in early-onset colorectal cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39919707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>The incidence of early-onset colorectal cancer (EO-CRC) is surging, and by 2030, one-third of all CRCs will occur before the commonly recommended screening age of 50 years. The time required for EO-CRC to reach the metastatic stage is unknown, yet this knowledge is critical to tailor early-diagnosis screening strategies. Here, we discuss how defining a key biological feature of EO-CRC may be central to protecting young adults from an alarming and probably unprecedented tumor epidemic.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 6;188(3):589-593. doi: 10.1016/j.cell.2024.12.003.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The incidence of early-onset colorectal cancer (EO-CRC) is surging, and by 2030, one-third of all CRCs will occur before the commonly recommended screening age of 50 years. The time required for EO-CRC to reach the metastatic stage is unknown, yet this knowledge is critical to tailor early-diagnosis screening strategies. Here, we discuss how defining a key biological feature of EO-CRC may be central to protecting young adults from an alarming and probably unprecedented tumor epidemic.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39919707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39919707</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.003>10.1016/j.cell.2024.12.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39919707</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Gianluca Mauri</dc:creator>
<dc:creator>Giorgio Patelli</dc:creator>
<dc:creator>Giovanni Crisafulli</dc:creator>
<dc:creator>Salvatore Siena</dc:creator>
<dc:creator>Alberto Bardelli</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Tumor "age" in early-onset colorectal cancer</dc:title>
<dc:identifier>pmid:39919707</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.003</dc:identifier>
</item>
<item>
<title>Inspiring the next generation of engineers and scientists to be champions of equitable change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39919706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>Nyasha Milanzi is a winner of the fifth annual Rising Black Scientists Awards for a scholar in the physical, data, earth, and environmental sciences. We asked emerging Black scientists to tell us about their scientific vision and goals, experiences that sparked their interest in science, how they want to contribute to a more inclusive scientific community, and how these all fit together on their journey. This is her story.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 6;188(3):586-588. doi: 10.1016/j.cell.2025.01.014.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Nyasha Milanzi is a winner of the fifth annual Rising Black Scientists Awards for a scholar in the physical, data, earth, and environmental sciences. We asked emerging Black scientists to tell us about their scientific vision and goals, experiences that sparked their interest in science, how they want to contribute to a more inclusive scientific community, and how these all fit together on their journey. This is her story.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39919706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39919706</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.014>10.1016/j.cell.2025.01.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39919706</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Nyasha Milanzi</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Inspiring the next generation of engineers and scientists to be champions of equitable change</dc:title>
<dc:identifier>pmid:39919706</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.014</dc:identifier>
</item>
<item>
<title>Retooling science: Transforming tools into instruments of equity as a Black physician-scientist</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39919705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>Victor Ekuta is a winner of the fifth annual Rising Black Scientists Awards for a scholar in the life and health sciences. We asked emerging Black scientists to tell us about their scientific vision and goals, the experiences that sparked their interest in science, how they want to contribute to a more inclusive scientific community, and how these all fit together on their journey. This is his story.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 6;188(3):582-584. doi: 10.1016/j.cell.2025.01.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Victor Ekuta is a winner of the fifth annual Rising Black Scientists Awards for a scholar in the life and health sciences. We asked emerging Black scientists to tell us about their scientific vision and goals, the experiences that sparked their interest in science, how they want to contribute to a more inclusive scientific community, and how these all fit together on their journey. This is his story.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39919705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39919705</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.010>10.1016/j.cell.2025.01.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39919705</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Victor Ekuta</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Retooling science: Transforming tools into instruments of equity as a Black physician-scientist</dc:title>
<dc:identifier>pmid:39919705</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.010</dc:identifier>
</item>
<item>
<title>Bridging worlds: A STEM journey from Nigeria to the US and back</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39919704/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>Kenna Gloria Agbugba is a winner of the fifth annual Rising Black Scientists Awards for a scholar in the physical, data, earth, and environmental sciences. We asked emerging Black scientists to tell us about their scientific vision and goals, the experiences that sparked their interest in science, how they want to contribute to a more inclusive scientific community, and how these all fit together on their journey. This is her story.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 6;188(3):578-580. doi: 10.1016/j.cell.2025.01.013.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Kenna Gloria Agbugba is a winner of the fifth annual Rising Black Scientists Awards for a scholar in the physical, data, earth, and environmental sciences. We asked emerging Black scientists to tell us about their scientific vision and goals, the experiences that sparked their interest in science, how they want to contribute to a more inclusive scientific community, and how these all fit together on their journey. This is her story.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39919704/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39919704</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.013>10.1016/j.cell.2025.01.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39919704</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Kenna Gloria Agbugba</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Bridging worlds: A STEM journey from Nigeria to the US and back</dc:title>
<dc:identifier>pmid:39919704</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.013</dc:identifier>
</item>
<item>
<title>The sounds of music: Tracing memories and pathways through research and resistance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39919703/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>Jheannelle Johnson is a winner of the fifth annual Rising Black Scientists Awards for a scholar in the life and health sciences. We asked emerging Black scientists to tell us about their scientific vision and goals, experiences that sparked their interest in science, how they want to contribute to a more inclusive scientific community, and how these all fit together on their journey. This is her story.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 6;188(3):574-576. doi: 10.1016/j.cell.2025.01.009.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Jheannelle Johnson is a winner of the fifth annual Rising Black Scientists Awards for a scholar in the life and health sciences. We asked emerging Black scientists to tell us about their scientific vision and goals, experiences that sparked their interest in science, how they want to contribute to a more inclusive scientific community, and how these all fit together on their journey. This is her story.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39919703/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39919703</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.009>10.1016/j.cell.2025.01.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39919703</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jheannelle Johnson</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The sounds of music: Tracing memories and pathways through research and resistance</dc:title>
<dc:identifier>pmid:39919703</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.009</dc:identifier>
</item>
<item>
<title>New light shed on sex-related risk factors and frailty</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918852/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 7;46(6):493-496. doi: 10.1093/eurheartj/ehae932.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918852/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918852</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae932>10.1093/eurheartj/ehae932</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918852</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New light shed on sex-related risk factors and frailty</dc:title>
<dc:identifier>pmid:39918852</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae932</dc:identifier>
</item>
<item>
<title>Correction to: Atheroma transcriptomics identifies ARNTL as a smooth muscle cell regulator and with clinical and genetic data improves risk stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 7:ehaf107. doi: 10.1093/eurheartj/ehaf107. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf107>10.1093/eurheartj/ehaf107</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918843</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Atheroma transcriptomics identifies ARNTL as a smooth muscle cell regulator and with clinical and genetic data improves risk stratification</dc:title>
<dc:identifier>pmid:39918843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf107</dc:identifier>
</item>
<item>
<title>Redefining Outcomes in Pediatric Cardiovascular Research: The Promise of Days Alive Out of Health Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918474/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 24:S0735-1097(25)00019-1. doi: 10.1016/j.jacc.2024.12.027. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918474/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918474</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.027>10.1016/j.jacc.2024.12.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918474</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Emily M Bucholz</dc:creator>
<dc:creator>John M Costello</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Redefining Outcomes in Pediatric Cardiovascular Research: The Promise of Days Alive Out of Health Care</dc:title>
<dc:identifier>pmid:39918474</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.027</dc:identifier>
</item>
<item>
<title>Setting Benchmarks for Long-Term Success of Surgical Mitral Valve Repair in Reference Centers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 25:S0735-1097(24)10484-6. doi: 10.1016/j.jacc.2024.11.018. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918473</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.018>10.1016/j.jacc.2024.11.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918473</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Makoto Mori</dc:creator>
<dc:creator>Arnar Geirsson</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Setting Benchmarks for Long-Term Success of Surgical Mitral Valve Repair in Reference Centers</dc:title>
<dc:identifier>pmid:39918473</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.018</dc:identifier>
</item>
<item>
<title>Under Pressure: The Prognostic Role of Blood Pressure in Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 22:S0735-1097(24)10659-6. doi: 10.1016/j.jacc.2024.11.049. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918472</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.049>10.1016/j.jacc.2024.11.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918472</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Stefano Masi</dc:creator>
<dc:creator>Hermann Dalpiaz</dc:creator>
<dc:creator>Gianluigi Savarese</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Under Pressure: The Prognostic Role of Blood Pressure in Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39918472</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.049</dc:identifier>
</item>
<item>
<title>Incorporating the Totality of Ischemic and Hemorrhagic Events: The Case of the AUGUSTUS Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 20:S0735-1097(24)10614-6. doi: 10.1016/j.jacc.2024.11.047. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918471</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.047>10.1016/j.jacc.2024.11.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918471</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Incorporating the Totality of Ischemic and Hemorrhagic Events: The Case of the AUGUSTUS Trial</dc:title>
<dc:identifier>pmid:39918471</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.047</dc:identifier>
</item>
<item>
<title>Long-Term Outcomes of Contemporary Surgical Repair for Degenerative Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This contemporary series provides further data on the low in-hospital mortality and excellent long-term outcomes of surgical mitral repair when performed in a high-volume center. Preoperative symptoms are associated with worse outcomes. Isolated anterior leaflet disease increases the risk of reoperation, heart failure rehospitalization, and late mortality compared to posterior or bileaflets pathology.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 16:S0735-1097(24)10356-7. doi: 10.1016/j.jacc.2024.10.108. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: There are limited published reports about the long-term outcomes of contemporary surgical mitral repair series for degenerative mitral regurgitation performed at a high-volume center.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study is to report independently adjudicated long-term results of contemporary mitral repair surgery performed at a high-volume center.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A retrospective study was conducted on 3,317 patients who underwent surgical mitral repair for degenerative mitral regurgitation at a tertiary care center between January 1, 2008 and December 31, 2017. Follow-up data, focusing on survival, reinterventions, and heart failure rehospitalizations were adjudicated and analyzed by the Italian National Agency for Regional Healthcare Services. Echocardiographic assessments during follow-up were not included. Complete (100%) data linkage was achieved.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The median age of the patients was 57 years, and 68.56% were men. The overall in-hospital mortality was 0.48% (16 of 3,317) for all cases and 0.21% (5 of 2,399) in isolated mitral valve repair. The 10-year survival was 89.65% (95% CI: 88.75%-90.55%), independently associated with preoperative symptoms and anterior leaflet disease. Freedom from reoperation was 96.63% (95% CI: 95.63%-97.63%) at 10 years. Anterior leaflet disease, a second run of cardiopulmonary bypass, and more than mild mitral regurgitation at discharge were associated with increased risk of reoperation. Finally, 10-year freedom from rehospitalization for heart failure was 92.24% (95% CI: 90.62%-93.86%), with age, prior hospitalization for heart failure, preoperative symptoms, and anterior leaflet disease identified as independent risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This contemporary series provides further data on the low in-hospital mortality and excellent long-term outcomes of surgical mitral repair when performed in a high-volume center. Preoperative symptoms are associated with worse outcomes. Isolated anterior leaflet disease increases the risk of reoperation, heart failure rehospitalization, and late mortality compared to posterior or bileaflets pathology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918470</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.108>10.1016/j.jacc.2024.10.108</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918470</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Benedetto Del Forno</dc:creator>
<dc:creator>Guido Ascione</dc:creator>
<dc:creator>Davide Carino</dc:creator>
<dc:creator>Mariangela D'Ovidio</dc:creator>
<dc:creator>Elisabetta Lapenna</dc:creator>
<dc:creator>Alessandro Verzini</dc:creator>
<dc:creator>Paolo Denti</dc:creator>
<dc:creator>Andrea Blasio</dc:creator>
<dc:creator>Nicolò Azzola Guicciardi</dc:creator>
<dc:creator>Anna Mara Scandroglio</dc:creator>
<dc:creator>Fabrizio Monaco</dc:creator>
<dc:creator>Eustachio Agricola</dc:creator>
<dc:creator>Marina Davoli</dc:creator>
<dc:creator>Giorgia Duranti</dc:creator>
<dc:creator>Giovanni Baglio</dc:creator>
<dc:creator>Enrico Coscioni</dc:creator>
<dc:creator>Alessandro Castiglioni</dc:creator>
<dc:creator>Ottavio Alfieri</dc:creator>
<dc:creator>Michele De Bonis</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Outcomes of Contemporary Surgical Repair for Degenerative Mitral Regurgitation</dc:title>
<dc:identifier>pmid:39918470</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.108</dc:identifier>
</item>
<item>
<title>Days Alive Out of Health Care: A Novel Measure of Health Status After Congenital Heart Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this data set of children with Medicaid coverage, total DAoH is an easily reproducible, patient-centered outcome that should be considered for assessment of longitudinal outcomes for neonates and infants undergoing cardiac surgery. Where outpatient data are not available, days alive and out of hospital might serve as a reasonable alternative.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28:S0735-1097(24)10561-X. doi: 10.1016/j.jacc.2024.11.046. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: As pediatric and adult operative mortality improves, longitudinal outcomes beyond survival become increasingly important. "Days alive and out of hospital" is well-studied as a longitudinal, patient-centered outcome in adult populations. However, it has yet to be validated for children, whose health care use and survival differ from that of adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate days alive and out of health care/hospital as outcomes for neonatal and infant cardiac surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using linked, locally held, clinical registry data, the National Death Index, and Medicaid claims from the CHS-COLOUR (New York Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources), we describe and compare the distribution of days alive and out of health care/hospital (730 days or date of death minus date of birth, minus the sum of days in health care) over 2 years for New York State Medicaid-enrolled children who underwent initial neonatal or infant cardiac surgery during 2006 to 2018. We assess relative contributions of mortality, inpatient, and outpatient days, test impacts of alternate outpatient day weightings, and assess associations with patient characteristics known to be associated with other, established congenital heart surgical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 2,519 Medicaid-enrolled neonates/infants underwent initial cardiac surgery in the first year of life across New York state during 2006 to 2018. Days alive and out of health care (DAoH) (0-730 days) was bimodally distributed, with 10.4% (n = 261) spending &lt;100 days and 21.6% (n = 545) spending >;700 DAoH. We found that 5.9% (n = 149) of children died during their birth admission (0 DAoH). Cardiac disease complexity, weight at surgery, noncardiac preoperative comorbidities, and other preoperative risk factors were all significantly associated with the outcomes (P &lt;0.001). When considering only inpatient days, the distribution was more left-skewed, because 40% of health care days in the second year of life was attributable to outpatient days. Our findings were otherwise largely insensitive to health care type weightings.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this data set of children with Medicaid coverage, total DAoH is an easily reproducible, patient-centered outcome that should be considered for assessment of longitudinal outcomes for neonates and infants undergoing cardiac surgery. Where outpatient data are not available, days alive and out of hospital might serve as a reasonable alternative.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918469</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.046>10.1016/j.jacc.2024.11.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918469</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sarah Crook</dc:creator>
<dc:creator>Chantal M Sanchez</dc:creator>
<dc:creator>Kacie Dragan</dc:creator>
<dc:creator>Joyce L Woo</dc:creator>
<dc:creator>Pengfei Jiang</dc:creator>
<dc:creator>Matthew Neidell</dc:creator>
<dc:creator>Brett R Anderson</dc:creator>
<dc:creator>New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources (CHS-COLOUR)</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Days Alive Out of Health Care: A Novel Measure of Health Status After Congenital Heart Surgery</dc:title>
<dc:identifier>pmid:39918469</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.046</dc:identifier>
</item>
<item>
<title>Early Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: New Treatment Paradigms</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918468/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 24:S0735-1097(24)10715-2. doi: 10.1016/j.jacc.2024.12.019. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918468/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918468</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.019>10.1016/j.jacc.2024.12.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918468</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yousif Ahmad</dc:creator>
<dc:creator>Rohin K Reddy</dc:creator>
<dc:creator>James P Howard</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Early Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: New Treatment Paradigms</dc:title>
<dc:identifier>pmid:39918468</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.019</dc:identifier>
</item>
<item>
<title>Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with AF and recent ACS or PCI, apixaban significantly reduced total bleeding risk compared with VKA. Aspirin doubled total bleeding risk compared with placebo without a significant change in total ischemic events. Based on this assessment of total events, our findings support the use of apixaban plus a low-potency P2Y(12) inhibitor (ie, clopidogrel) without aspirin as the standard therapy for this high-risk patient population. (A Study of Apixaban in Patients With...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 24:S0735-1097(24)10555-4. doi: 10.1016/j.jacc.2024.10.125. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Limited data exist on the optimal antithrombotic strategy to minimize total bleeding and ischemic events for patients with recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) and atrial fibrillation (AF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to identify the antithrombotic regimen that minimized total major or clinically relevant nonmajor bleeding events, ischemic events, and hospitalizations after ACS or PCI in AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a secondary analysis of AUGUSTUS (Open-label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), a 2×2 factorial, randomized trial evaluating apixaban vs a vitamin K antagonist (VKA) and aspirin vs placebo in patients with AF and ACS or PCI who were on P2Y<sub>12</sub> inhibitor therapy. We determined the incidence of total major or clinically relevant nonmajor bleeding events in patients receiving at least 1 dose of study therapy, total ischemic events, and total hospitalizations among patients randomized to each antithrombotic strategy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over 6 months of follow-up, 573 of 4,568 (12.5%) patients experienced at least 1 bleeding event while on study drug; among them, 110 (19.2%) had multiple bleeding events. Compared with those with 1 bleeding event, patients with multiple bleeding events were more likely to be on a high-potency P2Y<sub>12</sub> inhibitor (prasugrel or ticagrelor vs clopidogrel). Of the 4,614 randomized participants, 219 (4.7%) had at least 1 ischemic event, among whom 75 (34.2%) had multiple ischemic events. At least 1 hospitalization occurred in 1,125 (24.4%) patients; among them, 384 (34.1%) had multiple hospitalizations. Apixaban, compared with VKA, significantly reduced the risk of total bleeding (rate ratio [RR]: 0.66; 95% CI: 0.55-0.80). Apixaban had similar rates of total ischemic events (RR: 0.83; 95% CI: 0.58-1.20) and total hospitalizations (RR: 0.90; 95% CI: 0.79-1.03) compared with VKA. Aspirin, compared with placebo, significantly increased the risk of total bleeding (RR: 2.14; 95% CI: 1.75-2.60). The rates of total ischemic events (RR: 0.75; 95% CI: 0.52-1.08) and total hospitalizations (RR: 1.11; 95% CI: 0.97-1.27) with aspirin and placebo were similar.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with AF and recent ACS or PCI, apixaban significantly reduced total bleeding risk compared with VKA. Aspirin doubled total bleeding risk compared with placebo without a significant change in total ischemic events. Based on this assessment of total events, our findings support the use of apixaban plus a low-potency P2Y<sub>12</sub> inhibitor (ie, clopidogrel) without aspirin as the standard therapy for this high-risk patient population. (A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis [Blood Clots] Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart; NCT02415400).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918467</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.125>10.1016/j.jacc.2024.10.125</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918467</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Manasi Tannu</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Daniel M Wojdyla</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Ronald Aronson</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS</dc:title>
<dc:identifier>pmid:39918467</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.125</dc:identifier>
</item>
<item>
<title>Unlocking Therapeutic Potential for Cardiac Remodeling in Obesity-Related HFpEF: Lessons From the SUMMIT CMR Substudy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 24:S0735-1097(24)10665-1. doi: 10.1016/j.jacc.2024.12.013. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918466</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.013>10.1016/j.jacc.2024.12.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918466</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Carlos E Rochitte</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Unlocking Therapeutic Potential for Cardiac Remodeling in Obesity-Related HFpEF: Lessons From the SUMMIT CMR Substudy</dc:title>
<dc:identifier>pmid:39918466</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.013</dc:identifier>
</item>
<item>
<title>Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918465/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250209031203&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with AF and stable CAD, OAC monotherapy, compared with OAC plus SAPT, was not associated with a statistically significant increased risk of ischemic events but resulted in a significantly reduced risk of bleeding.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 17:S0735-1097(25)00071-3. doi: 10.1016/j.jacc.2024.12.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The optimal long-term antithrombotic strategy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains uncertain. Individual randomized controlled trials (RCTs) had variations in their reported results and were not powered for effectiveness outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to pool the results of RCTs comparing the effectiveness and safety of oral anticoagulation (OAC) monotherapy vs OAC plus single antiplatelet therapy (SAPT) in patients with AF and stable CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We systematically searched PubMed, Embase, and ClinicalTrials.gov until September 09, 2024. The primary effectiveness outcome was a composite of myocardial infarction, ischemic stroke, systemic embolism, or death. The primary safety outcome was major bleeding. We obtained unpublished results from principal investigators of the included RCTs, as needed, to calculate pooled HRs and 95% CIs and to perform prespecified subgroup analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 690 screened records, 4 RCTs with 4,092 randomized patients were included (2 using edoxaban, 1 using rivaroxaban, and 1 using any oral anticoagulant; mean age 73.9 years, 20.1% women). The median follow-up durations ranged from 12 to 30 months (overall estimated weighted mean follow-up of 21.9 months). There were no statistically significant differences between OAC monotherapy vs OAC plus SAPT in the primary effectiveness outcome (7.3% vs 8.2%; HR: 0.90; 95% CI: 0.72-1.12), myocardial infarction (1.0% vs 0.7%; HR: 1.51; 95% CI: 0.75-3.04), ischemic stroke (1.9% vs 2.1%; HR: 0.89; 95% CI: 0.57-1.37), all-cause death (4.2% vs 5.3%; HR: 0.94; 95% CI: 0.49-1.80), or cardiovascular death (2.4% vs 3.0%; HR: 0.79; 95% CI: 0.54-1.15). OAC monotherapy was associated with a lower risk of major bleeding than OAC plus SAPT (3.3% vs 5.7%; HR: 0.59; 95% CI: 0.44-0.79). Subgroup analyses did not show significant interactions for effectiveness but suggested that the magnitude of bleeding reduction may be greater among men (P<sub>interaction</sub> = 0.03) and among patients with diabetes mellitus (P<sub>interaction</sub> = 0.04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with AF and stable CAD, OAC monotherapy, compared with OAC plus SAPT, was not associated with a statistically significant increased risk of ischemic events but resulted in a significantly reduced risk of bleeding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918465/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250209031203&v=2.18.0.post9+e462414">39918465</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.030>10.1016/j.jacc.2024.12.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918465</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sina Rashedi</dc:creator>
<dc:creator>Mohammad Keykhaei</dc:creator>
<dc:creator>Alyssa Sato</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:creator>John W Eikelboom</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:creator>Satoshi Yasuda</dc:creator>
<dc:creator>Hisao Ogawa</dc:creator>
<dc:creator>Satoshi Shizuta</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Yasuo Okumura</dc:creator>
<dc:creator>Felicita Andreotti</dc:creator>
<dc:creator>Laurent Bertoletti</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials</dc:title>
<dc:identifier>pmid:39918465</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.030</dc:identifier>
</item>





























</channel>
</rss>